BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Litigation with Schall Law Firm

Schall Law Firm, a national litigation firm focused on shareholder rights litigation, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. (“Bolt” or “the Company”) (NASDAQ: BOLT) for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between February 5, 2021 and May 14, 2024, inclusive (the “Class Period”), are encouraged to contact the Firm before September 3, 2024.